Comparison of Ruxolitinib and a Collagen-Targeted PTH-Based Hair Cycle Stimulant on Hair Follicle Counts and Hair Growth in the C3H/HeJ Engrafted Mouse Model of Alopecia Areata

    May 2023
    Robert C. Gensure
    Studysummary In this study using C3H/HeJ mice, a single subcutaneous injection of the fusion protein PTH-CBD increased anagen hair follicle counts and promoted hair regrowth comparably to daily oral ruxolitinib, potentially by enhancing beta-catenin production and stimulating anagen transition.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on morressier.com →
    Discuss this study in the Community →

    Related research 8

    1. CXCL12 Neutralizing Antibody Promotes Hair Growth in Androgenic Alopecia and Alopecia Areata International Journal of Molecular Sciences · 2024
    2. Advances in Hair Growth: Beneficial Effects of a New Product Formulated with Amplex Plus Technology on Hair Follicles Regeneration 2023
    3. Ruxolitinib for the Treatment of Severe Alopecia Areata Journal of the American Academy of Dermatology · 2018
    4. Treatments of Hereditary Hair Loss (Alopecia) 2018
    5. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    6. Androgenetic Alopecia and Its Remedies: A Review Journal of drug discovery and therapeutics · 2014
    7. Exogenous Stimulations Change Nude Mouse Hair Cycle Pattern Journal of dermatological treatment · 2010
    8. Treatment of Hair Loss The New England Journal of Medicine · 1999